The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lapatinib in combination with ECF/x in EGFR1 positive first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071).
Markus Hermann Moehler
No relevant relationships to disclose
Arno Schad
No relevant relationships to disclose
Murielle E. Mauer
No relevant relationships to disclose
Michel Praet
No relevant relationships to disclose
Francisco J. Sapunar
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Kathryn Jane Briggs
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Manfred P. Lutz
No relevant relationships to disclose
Arnaud Roth
No relevant relationships to disclose